{"id":35015,"date":"2023-02-08T12:37:58","date_gmt":"2023-02-08T11:37:58","guid":{"rendered":"https:\/\/ellipse.prbb.org\/?p=35015"},"modified":"2026-02-24T11:50:46","modified_gmt":"2026-02-24T10:50:46","slug":"medicina-viva-contra-les-afeccions-pulmonars","status":"publish","type":"post","link":"https:\/\/ellipse.prbb.org\/ca\/medicina-viva-contra-les-afeccions-pulmonars\/","title":{"rendered":"Medicina viva contra les afeccions pulmonars"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">L\u2019any 2021 el <a rel=\"noopener noreferrer\" href=\"https:\/\/www.crg.eu\/\" target=\"_blank\">Centre de Regulaci\u00f3 Gen\u00f2mica (CRG)<\/a> i la seva <em>spin-off <\/em><a href=\"https:\/\/www.pulmobio.com\/\" target=\"_blank\" rel=\"noreferrer noopener\">Pulmobiotics<\/a> van treballar junts per a <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/la-primera-pindola-viva-per-tractar-infeccions-resistents-als-antibiotics\/\" target=\"_blank\">desenvolupar la primera <strong>\u2018p\u00edndola viva\u2019<\/strong><\/a>. Una versi\u00f3 modificada i no infecciosa del bacteri <strong><em>Mycoplasma pneumonia <\/em><\/strong>(un dels bacteris m\u00e9s petits existents, i adaptat naturalment al pulm\u00f3). Aquesta &#8216;p\u00edndola&#8217; \u00e9s capa\u00e7 de produir, un cop arriba al pulm\u00f3, mol\u00e8cules per a tractar diverses patologies. Des de llavors, l\u2019equip d\u2019en <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/luis-serrano-crg-les-dones-contribueixen-a-millorar-la-ciencia\/\" target=\"_blank\"><strong>Luis Serrano<\/strong><\/a>, director del CRG, treballa per a trobar noves aplicacions d\u2019aquesta \u2018p\u00edndola viva\u2019.<\/p>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">Tractant les infeccions respirat\u00f2ries<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">En un <a href=\"https:\/\/www.crg.eu\/en\/news\/living-medicine-created-tackle-drug-resistant-lung-infections\" target=\"_blank\" rel=\"noopener noreferrer\">estudi recent<\/a>, l\u2019equip de Serrano ha modificat <em>M. pneumonia <\/em>per a que, a m\u00e9s de ser inn\u00f2cua, produeixi mol\u00e8cules capaces de <strong>matar i inhibir el creixement <\/strong>de <em>Pseudomonas aeruginosa<\/em>. Aquest bacteri que habita els tubs endotraqueals dels pacients intubats, produeix <strong>pneum\u00f2nia associada al ventilador<\/strong> en un de cada quatre pacients i \u00e9s altament resistent als antibi\u00f2tics.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">L\u2019\u00fas del nou tractament juntament amb dosis baixes d\u2019antibi\u00f2tics &#8211; que per s\u00ed sols no tenen efecte -, ha mostrat que la \u2018p\u00edndola viva\u2019 no \u00e9s t\u00f2xica per als <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/arnau-busquets-imim-els-cientifics-som-els-primers-que-volem-el-benestar-dels-animals-si-lanimal-no-esta-be-el-resultat-no-sera-valid\/\" target=\"_blank\">pulmons dels ratolins<\/a>, que redueix la infecci\u00f3 bacteriana (duplicant la taxa de superviv\u00e8ncia en ratolins) i que, a m\u00e9s, \u00e9s segura: en 4 dies l\u2019organisme elimina per s\u00ed mateix el bacteri modificat.<\/p>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<blockquote class=\"wp-block-quote is-layout-flow wp-block-quote-is-layout-flow\"><p>\u201cEl tractament obre orificis a les parets cel\u00b7lulars de P. aeruginosa i crea uns punts d\u2019entrada fonamentals per a que els antibi\u00f2tics les envaeixin i eliminin la infecci\u00f3 al seu origen\u201d <br><strong>Maria Lluch<\/strong>, Pulmobiotics<\/p><\/blockquote>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p class=\"wp-block-paragraph\">Encara que cal seguir estudiant aquest tractament abans que pugui entrar en <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/assaigs-clinics-el-llarg-cami-del-desenvolupament-de-nous-farmacs\/\" target=\"_blank\">fase d\u2019assaig cl\u00ednic<\/a>, s\u2019espera que la seva administraci\u00f3 sigui en forma de nebulitzador. Per\u00f2, en qualsevol cas, els bons resultats ratifiquen l\u2019\u00fas de la \u2018p\u00edndola viva\u2019 com a <strong>f\u00e0brica temporal de producci\u00f3 localitzada<\/strong>.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Aix\u00ed ho a demostrat tamb\u00e9 l\u2019equip en construir una \u2018p\u00edndola viva\u2019 capa\u00e7 de <strong>reduir la inflamaci\u00f3 <\/strong>que provoca la infecci\u00f3 per <em>Pseudomonas aeruginosa<\/em>. Gr\u00e0cies a l\u2019\u00fas de programes inform\u00e0tics han dissenyat una versi\u00f3 millorada de la citocina IL-10, una mol\u00e8cula antiinflamat\u00f2ria alliberada durant la resposta immune, i l\u2019han introdu\u00efda a la \u2018p\u00edndola viva\u2019. La seva aplicaci\u00f3 en ratolins ha demostrat que \u00abla IL-10 millorada portada directament al pulm\u00f3 \u00e9s capa\u00e7 de reduir la inflamaci\u00f3 de forma m\u00e9s eficient\u00bb, comenta l\u2019<strong>Ariadna Montero-Blay<\/strong>, primera autora de l\u2019estudi.<\/p>\n\n\n\n<div style=\"height:23px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<h3 class=\"wp-block-heading\">1,9M d\u2019euros per al c\u00e0ncer de pulm\u00f3<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\"><a rel=\"noopener noreferrer\" href=\"https:\/\/www.pulmobio.com\/\" target=\"_blank\"><strong>Pulmobiotics <\/strong><\/a>\u00e9s la<strong> <em>spin-off <\/em><\/strong>que <strong>Maria Lluch <\/strong>i Luis Serrano van crear l\u2019any 2020, l\u2019objectiu de la qual \u00e9s desenvolupar aplicacions terap\u00e8utiques per a les afeccions pulmonars. I <a rel=\"noopener noreferrer\" href=\"https:\/\/www.crg.eu\/en\/news\/pulmobiotics-receives-19m-euros-develop-living-medicine-lung-cancer\" target=\"_blank\">recentment ha rebut<\/a> una ajuda de <strong>1,9 milions d\u2019euros <\/strong>de la convocat\u00f2ria <em>Transition Challenge <\/em>del Consell Europeu d\u2019Innovaci\u00f3. Aquests diners es destinaran a dissenyar una \u2018p\u00edndola viva\u2019 per a ajudar en el tractament <strong>contra els carcinomes pulmonars no miocr\u00edtics<\/strong>, el <strong>tipus de <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/investigant-el-paper-del-metabolisme-cellular-en-el-cancer-de-pulmo\/\" target=\"_blank\">c\u00e0ncer de pulm\u00f3 <\/a><\/strong>m\u00e9s com\u00fa. Aquest c\u00e1ncer acostuma a desenvolupar resist\u00e8ncia al <a rel=\"noopener noreferrer\" href=\"https:\/\/ellipse.prbb.org\/ca\/avancant-en-la-recerca-de-la-immunoterapia\/\" target=\"_blank\">tractament<\/a> habitual (un tipus d\u2019immunoter\u00e0pia), aix\u00ed com toxicitat. L\u2019equip cient\u00edfic proposa doncs complementar aquest tractament amb una \u2018p\u00edndola viva\u2019 reprogramada per a activar el sistema immunitari a l\u2019interior i al voltant del tumor. S\u2019espera que aix\u00f2 ajudi a desencadenar una resposta immune localitzada al pulm\u00f3 que eviti danys en teixits sans i els usuals efectes secundaris.<\/p>\n\n\n\n<div style=\"height:46px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>El CRG i l&#8217;spin-off Pulmobiotics treballen junts desenvolupant \u2018p\u00edndoles vives&#8217; que, mitjan\u00e7ant un bacteri modificat per a produir mol\u00e8cules d\u2019inter\u00e8s, podran tractar des de la pneum\u00f2nia associada al ventilador fins al c\u00e0ncer de pulm\u00f3 m\u00e9s com\u00fa. <\/p>\n","protected":false},"author":29,"featured_media":35013,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[477,307,265,726,670],"new-type":[35],"class_list":["post-35015","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-recerca","tag-bacteris","tag-biologia-sintetica","tag-crg-ca","tag-innovacio","tag-respiratori","new-type-noticies"],"acf":[],"_links":{"self":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/35015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/users\/29"}],"replies":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/comments?post=35015"}],"version-history":[{"count":6,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/35015\/revisions"}],"predecessor-version":[{"id":50682,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/posts\/35015\/revisions\/50682"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media\/35013"}],"wp:attachment":[{"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/media?parent=35015"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/categories?post=35015"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/tags?post=35015"},{"taxonomy":"new-type","embeddable":true,"href":"https:\/\/ellipse.prbb.org\/ca\/wp-json\/wp\/v2\/new-type?post=35015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}